AGX expects 10.36% EPS decline, is this priced in or a buying opportunity? OXM projects 96.35% EPS drop, does this signal deeper operational risks? VERI forecasts 60% EPS growth despite negative earnings, what drives this optimism? BAK anticipates 151.28% EPS plunge, are short-term headwinds masking long-term value? ACOG's 47.06% EPS improvement still negative, is the growth trajectory sustainable?

``` The deep research logic is organized as follows: Okay, let's tackle this question. The user is asking about five stocks—AGX, OXM, VERI, BAK, and ACOG—and whether their expected EPS changes are priced in or present buying opportunities, or if there are deeper risks or sustainable growth. First, I need to check the references provided. The user included a lot of data, so I'll start by looking at the closing prices and recent news for each stock. For AGX (Argan), the closing price is $405.95, down 7.21%. There's a mention of institutional buying, like HWG Holdings taking a position. The EPS estimate is a 10.36% decline. The user is asking if this decline is priced in. I should look at the stock's performance, technical indicators, and analyst ratings. The RSI is neutral, and there are mixed analyst ratings. The stock has a high market cap, so maybe it's undervalued despite the decline. Next, OXM (Oxford Industries) has a closing price of $32.73, down 0.74%. The EPS is expected to drop by 96.35%, which is a huge drop. The user is concerned about operational risks. The company has lowered guidance, and there's a bearish candlestick pattern. The stock is trading near its 52-week low, which might indicate that the market has already priced in some of the bad news. However, the high short interest could mean more downside risk. VERI (Veritone) closed at $2.66, down 1.18%. The EPS forecast is a 60% growth, but they're still negative. The user is asking what drives this optimism. The company has a modular AI platform, which is a growth area. There's recent analyst upgrades and a focus on tokenization. The technicals show oversold conditions, which might attract contrarian investors. However, the stock is highly volatile, so the risk is high. BAK (Braskem) closed at $3.95, down 6.89%. The EPS is expected to plunge 151.28%. The user wants to know if short-term headwinds mask long-term value. The company is dealing with governance issues and weak spreads, but there's a potential restructuring. The stock is undervalued compared to peers, but the risks are significant with high debt and regulatory concerns. ACOG (Alpha Cognition) closed at $5.17, down 2.82%. The EPS is improving by 47.06%, but still negative. The user is asking about sustainability. The company has a new product launch and institutional buying. The technicals are bearish, but the short interest is high, indicating potential upside if the product succeeds. However, the market is skeptical given the high volatility and past performance. Putting it all together, I need to structure the answer with a conclusion first, then detailed analysis for each stock. Use tables to present the data clearly. Make sure to cite the references properly and include the visualizations where needed. Also, keep the language professional but engaging, using emojis to make it more approachable. ``` ### 🎯 **Conclusion** **AGX**: The 10.36% EPS decline is partially priced in, but the stock remains undervalued with institutional confidence. **OXM**: The 96.35% EPS drop signals significant operational risks, with limited upside potential. **VERI**: The 60% EPS growth optimism hinges on AI-driven innovation, but execution risks persist. **BAK**: The 151.28% EPS plunge reflects short-term headwinds, but long-term restructuring could unlock value. **ACOG**: The 47.06% EPS improvement is encouraging, but sustainability depends on product adoption and debt management. --- ### 📊 **Detailed Analysis** #### **1. Argan Inc. (AGX)** | Metric | Data (2026-03-26) | Context | |------------------------|--------------------|---------------------------------------------------------------------------| | Closing Price | $405.95 | Down 7.21% YoY, near 52-week low ($111.16–$492.70) | | EPS Estimate (Q4 2026) | $1.99 (-10.36%) | Analysts expect a 10.36% decline YoY | | Institutional Activity | +$2.48M | HWG Holdings LP acquired 7,928 shares (0.06% stake) | | Technicals | RSI: 48.16 (Neutral), MACD: Buy Signal | Neutral momentum, but oversold conditions | | Analyst Consensus | Hold (Avg. Target: $355.20) | Mixed ratings (3 Buy, 6 Hold, 0 Sell) | **Analysis**: Argan’s stock price reflects market skepticism about its ability to sustain growth amid macroeconomic uncertainties. However, institutional buying and a favorable MACD signal suggest undervaluation. The 10.36% EPS decline is partially priced in, but the stock remains attractive for long-term infrastructure plays. --- #### **2. Oxford Industries Inc. (OXM)** | Metric | Data (2026-03-26) | Context | |------------------------|--------------------|---------------------------------------------------------------------------| | Closing Price | $32.73 | Down 0.74% YoY, near 52-week low ($111.16–$492.70) | | EPS Estimate (Q4 2026) | $0.05 (-96.35%) | Analysts expect a 96.35% YoY decline | | Operational Risks | Tariffs, Supply Chain | Company slashed FY2026 guidance due to tariff impacts | | Technicals | Bearish Candlestick | Falling Three Methods pattern | | Analyst Consensus | Hold (Avg. Target: $36.50) | Mixed ratings (1 Buy, 2 Hold, 1 Sell) | **Analysis**: Oxford Industries faces severe headwinds from tariffs and supply chain disruptions. The 96.35% EPS drop signals deeper operational risks, and the stock’s bearish technicals suggest further downside. Investors should avoid unless there’s a catalyst like tariff resolution. --- #### **3. Veritone Inc. (VERI)** | Metric | Data (2026-03-26) | Context | |------------------------|--------------------|---------------------------------------------------------------------------| | Closing Price | $2.66 | Down 1.18% YoY, near 52-week low ($1.22–$9.42) | | EPS Estimate (Q4 2026) | -$0.09 (+60%) | Analysts project a 60% YoY improvement (still negative) | | Growth Drivers | AI Tokenization | Veritone’s modular AI platform targets unstructured data monetization | | Technicals | Oversold (RSI: 38.35) | Stochastic RSI: Oversold | | Analyst Consensus | Hold (Avg. Target: $11.00) | Mixed ratings (2 Buy, 1 Hold, 1 Sell) | **Analysis**: Veritone’s optimism stems from its AI-driven innovation, but the stock remains highly speculative. The 60% EPS growth (from -$0.13 to -$0.09) reflects early-stage progress, but execution risks are high. The oversold technicals could attract contrarian investors, but caution is advised. --- #### **4. Braskem S.A. (BAK)** | Metric | Data (2026-03-26) | Context | |------------------------|--------------------|---------------------------------------------------------------------------| | Closing Price | $3.95 | Down 6.89% YoY, near 52-week low ($1.22–$9.42) | | EPS Estimate (Q4 2026) | -$0.98 (-151.28%) | Analysts project a 151.28% YoY decline | | Operational Risks | Weak Spreads, Debt | Petrobras’ stake sale and high leverage | | Technicals | Bearish (RSI: 38.35) | Oversold conditions | | Analyst Consensus | Hold (Avg. Target: $4.40) | Mixed ratings (1 Buy, 2 Hold, 1 Sell) | **Analysis**: Braskem’s stock reflects short-term headwinds from weak petrochemical spreads and high debt. However, the potential restructuring and Petrobras’ stake sale could unlock long-term value. The 151.28% EPS plunge is a red flag, but the stock’s undervaluation (P/E: -4.04) suggests contrarian opportunities. --- #### **5. Alpha Cognition Inc. (ACOG)** | Metric | Data (2026-03-26) | Context | |------------------------|--------------------|---------------------------------------------------------------------------| | Closing Price | $5.17 | Down 2.82% YoY, near 52-week low ($3.75–$11.54) | | EPS Estimate (Q4 2026) | -$0.27 (+47.06%) | Analysts project a 47.06% YoY improvement (still negative) | | Growth Drivers | ZUNVEYL Launch | Alzheimer’s drug shows early adoption (2,038 nursing homes) | | Technicals | Bearish (RSI: 38.57) | Oversold conditions | | Analyst Consensus | Buy (Avg. Target: $18.00) | HC Wainwright reiterates Buy | **Analysis**: Alpha Cognition’s EPS improvement reflects progress in its ZUNVEYL drug, but sustainability depends on regulatory approvals and market adoption. The stock’s high short interest (39.0%) suggests potential upside, but risks remain due to negative earnings and high volatility. --- ### 📊 **Final Takeaway** - **AGX**: Hold for long-term infrastructure exposure. - **OXM**: Avoid due to operational risks. - **VERI**: Speculative buy for AI innovation. - **BAK**: High-risk contrarian play. - **ACOG**: Monitor for ZUNVEYL adoption. |market_code|code|Ticker|Name|Date|Closing Price| |---|---|---|---|---|---| |169|AGX|AGX.N|Argan|20250326|119.52| |185|VERI|VERI.O|Veritone|20250326|2.66| |186|ACOG|ACOG.O|Alpha Cognition|20250326|5.52| |169|OXM|OXM.N|Oxford Industries|20250326|61.77| |169|BAK|BAK.N|Braskem Pref ADR|20250326|4.13| |169|AGX|AGX.N|Argan|20250327|115.23| |185|VERI|VERI.O|Veritone|20250327|2.74| |186|ACOG|ACOG.O|Alpha Cognition|20250327|5.31| |169|OXM|OXM.N|Oxford Industries|20250327|62.54| |169|BAK|BAK.N|Braskem Pref ADR|20250327|4.08|